| Jennifer Anderson, | |
|
400 22nd Ave, Brookings, SD 57006-2450 | |
| (605) 697-9500 | |
| (605) 697-6939 |
| Full Name | Jennifer Anderson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 400 22nd Ave, Brookings, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851797948 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | CP000909 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera De Smet Memorial Hospital - Cah | De smet, SD | Hospital |
| Brookings Health System | Brookings, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Avera Queen Of Peace | 9335050806 | 84 |
News Archive
Hologic, Inc. has announced the publication of the first of its kind study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth. The study, "Does fetal fibronectin testing change patient management in women at risk of preterm labour?" by researchers at King's College, London, England appears in the on-line version of the European Journal of Obstetrics & Gynecology and Reproductive Biology.
The Times of Zambia/allAfrica.com examines abortion in Zambia and efforts to reduce maternal mortality. "Unsafe abortions are one of the top five causes of maternal mortality in Zambia," writes the newspaper, which adds they are one factor keeping the country from meeting the U.N. Millennium Development Goal target of reducing maternal mortality.
Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.
› Verified 5 days ago
| Entity Name | Avera Queen Of Peace |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205359031 PECOS PAC ID: 9335050806 Enrollment ID: O20031229000301 |
News Archive
Hologic, Inc. has announced the publication of the first of its kind study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth. The study, "Does fetal fibronectin testing change patient management in women at risk of preterm labour?" by researchers at King's College, London, England appears in the on-line version of the European Journal of Obstetrics & Gynecology and Reproductive Biology.
The Times of Zambia/allAfrica.com examines abortion in Zambia and efforts to reduce maternal mortality. "Unsafe abortions are one of the top five causes of maternal mortality in Zambia," writes the newspaper, which adds they are one factor keeping the country from meeting the U.N. Millennium Development Goal target of reducing maternal mortality.
Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.
› Verified 5 days ago
| Entity Name | City Of Brookings |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932281029 PECOS PAC ID: 1052307105 Enrollment ID: O20040423000002 |
News Archive
Hologic, Inc. has announced the publication of the first of its kind study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth. The study, "Does fetal fibronectin testing change patient management in women at risk of preterm labour?" by researchers at King's College, London, England appears in the on-line version of the European Journal of Obstetrics & Gynecology and Reproductive Biology.
The Times of Zambia/allAfrica.com examines abortion in Zambia and efforts to reduce maternal mortality. "Unsafe abortions are one of the top five causes of maternal mortality in Zambia," writes the newspaper, which adds they are one factor keeping the country from meeting the U.N. Millennium Development Goal target of reducing maternal mortality.
Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.
› Verified 5 days ago
| Entity Name | Avera Queen Of Peace |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1710155460 PECOS PAC ID: 9335050806 Enrollment ID: O20080714000163 |
News Archive
Hologic, Inc. has announced the publication of the first of its kind study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth. The study, "Does fetal fibronectin testing change patient management in women at risk of preterm labour?" by researchers at King's College, London, England appears in the on-line version of the European Journal of Obstetrics & Gynecology and Reproductive Biology.
The Times of Zambia/allAfrica.com examines abortion in Zambia and efforts to reduce maternal mortality. "Unsafe abortions are one of the top five causes of maternal mortality in Zambia," writes the newspaper, which adds they are one factor keeping the country from meeting the U.N. Millennium Development Goal target of reducing maternal mortality.
Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Anderson, 400 22nd Ave, Brookings, SD 57006-2450 Ph: (605) 697-9500 | Jennifer Anderson, 400 22nd Ave, Brookings, SD 57006-2450 Ph: (605) 697-9500 |
News Archive
Hologic, Inc. has announced the publication of the first of its kind study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth. The study, "Does fetal fibronectin testing change patient management in women at risk of preterm labour?" by researchers at King's College, London, England appears in the on-line version of the European Journal of Obstetrics & Gynecology and Reproductive Biology.
The Times of Zambia/allAfrica.com examines abortion in Zambia and efforts to reduce maternal mortality. "Unsafe abortions are one of the top five causes of maternal mortality in Zambia," writes the newspaper, which adds they are one factor keeping the country from meeting the U.N. Millennium Development Goal target of reducing maternal mortality.
Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.
› Verified 5 days ago
Dr. Jennifer Ann Redmond, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 400 22nd Ave, Brookings, SD 57006 Phone: 605-697-9555 | |
Dr. Rachel Lynde, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 922 22nd Ave S, Brookings, SD 57006 Phone: 605-697-1900 | |
Anne Marie Mcnally, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 922 22nd Ave S, Brookings, SD 57006 Phone: 605-697-1900 | |
Ashleigh Eilts, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 922 22nd Ave S, Brookings, SD 57006 Phone: 605-697-1900 | |
Sarah Sapp, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 400 22nd Ave, Brookings, SD 57006 Phone: 605-697-9500 Fax: 605-697-6939 | |
Lindsay Marie Rheault, CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: Wellness Ctr, Box 2818, Brookings, SD 57007 Phone: 605-688-4157 | |
Janae Louise Jacobsen, RN, MS, CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1440 N Campus Dr, Wellness Center, Box 2818, Brookings, SD 57007 Phone: 605-688-4157 |